• Santhera to Develop, Market Polyphor Experimental CF Therapy
  • Arch Biopartners Enrolling Volunteers in Phase 1 Trial of AB569, Therapy Candidate for Drug-resistant Bacterial Lung Infections
  • Trial Investigating AzurRx’s Replacement Therapy for EPI Completes 75% Enrollment
  • Australian Scientist Gets $1 Million to See if Probiotics Can Help Children with CF
  • Let’s Talk About Marijuana
  • FDA Approves Symdeko, Vertex’s Combo Therapy for Patients with Certain Mutations in CFTR Gene
  • 2 CF Case Reports Show Successful Use of GM-CSF for Treating Nontuberculous Mycobacteria
  • Rare Disease Groups, Patients Differ on ‘Right to Try’ Bill Before US Congress
  • Learning to Live ‘Off-book’
  • Potential Therapy for CF Patients with Hearing Loss Due to Antibiotics OK’d for Clinical Trial
  • Introducing ‘This Lung Life,’ a Column by Ella Balasa
  • Anthera Concludes Last Patient Visit in Sollpura Trial for Exocrine Pancreatic Insufficiency in CF